Passive Targeted Drug Delivery of Venlafaxine HCl to the Brain by Modified Chitosan Nanoparticles: Characterization, Cellular Safety Assessment, and In Vivo Evaluation.

MLA

Saeedi, Majid, et al. “Passive Targeted Drug Delivery of Venlafaxine HCl to the Brain by Modified Chitosan Nanoparticles: Characterization, Cellular Safety Assessment, and In Vivo Evaluation.” Journal of Pharmaceutical Innovation, vol. 18, no. 3, Sept. 2023, pp. 1441–53. EBSCOhost, https://doi.org/10.1007/s12247-023-09733-6.

APA

Saeedi, M., Morteza-Semnani, K., Siahposht-Khachaki, A., Akbari, J., Valizadeh, M., Sanaee, A., Jafarkhani, B., Eghbali, M., Zanjani, H. H. H., Hashemi, S. M. H., & Rahimnia, S. M. (2023). Passive Targeted Drug Delivery of Venlafaxine HCl to the Brain by Modified Chitosan Nanoparticles: Characterization, Cellular Safety Assessment, and In Vivo Evaluation. Journal of Pharmaceutical Innovation, 18(3), 1441–1453. https://doi.org/10.1007/s12247-023-09733-6

Chicago

Saeedi, Majid, Katayoun Morteza-Semnani, Ali Siahposht-Khachaki, Jafar Akbari, Marjan Valizadeh, Alireza Sanaee, Behrouz Jafarkhani, et al. 2023. “Passive Targeted Drug Delivery of Venlafaxine HCl to the Brain by Modified Chitosan Nanoparticles: Characterization, Cellular Safety Assessment, and In Vivo Evaluation.” Journal of Pharmaceutical Innovation 18 (3): 1441–53. doi:10.1007/s12247-023-09733-6.